1. Show article details.

    Here's How Much $1000 Invested In West Pharmaceutical Servs 10 Years Ago Would Be Worth Today

    Benzinga – 12:37 PM ET 08/05/2022

    West Pharmaceutical Servs has outperformed the market over the past 10 years by 18.96% on an annualized basis producing an average annual return of 30.3%. Currently, West Pharmaceutical Servs has a market capitalization of $25.12 billion.

  2. Show article details.

    West Pharmaceutical Servs's Return On Capital Employed Insights

    Benzinga – 9:53 AM ET 08/03/2022

    According to Benzinga Pro, during Q2, West Pharmaceutical Servs earned $188.50 million, a 8.46% increase from the preceding quarter. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

  3. Show article details.

    How Is The Market Feeling About West Pharmaceutical Servs?

    Benzinga – 4:40 PM ET 08/02/2022

    West Pharmaceutical Servs's short percent of float has risen 6.5% since its last report. Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock.

  4. Show article details.

    West Pharmaceutical Services: Q2 Earnings Insights

    Benzinga – 7:13 AM ET 07/28/2022

      West Pharmaceutical Servs reported its Q2 earnings results on Thursday, July 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. West Pharmaceutical Servs beat estimated earnings by 11.76%, reporting an EPS of $2.47 versus an estimate of $2.21. Revenue was up $47.70 million from the same period last year.

  5. Show article details.

    BRIEF-West Pharma Reports Q2 Adj EPS Of $2.47

    Reuters – 6:08 AM ET 07/28/2022

    West Pharmaceutical Services Inc (WST) : * WEST ANNOUNCES SECOND-QUARTER 2022 RESULTS. * Q2 ADJUSTED EARNINGS PER SHARE $2.47. * Q2 EARNINGS PER SHARE $2.48. * Q2 NET SALES OF $771.3 MILLION GREW 6.6%; ORGANIC NET SALES GROWTH WAS 13.1% * SEES FULL-YEAR 2022 NET SALES ARE EXPECTED TO BE IN THE RANGE OF $2.950 BILLION TO $2.975 BILLION.

  6. Show article details.

    Earnings Scheduled For July 28, 2022

    Benzinga – 6:06 AM ET 07/28/2022

      ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  7. Show article details.

    West Announces Second-Quarter 2022 Results

    PR Newswire – 6:00 AM ET 07/28/2022

    - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 28, 2022  /PRNewswire/ -- WEST PHARMACEUTICAL SERVICES, INC. (WST) today announced its financial results for the second-quarter 2022 and updated full-year 2022 financial guidance.

  8. Show article details.

    Earnings Scheduled For July 28, 2022

    Benzinga – 5:06 AM ET 07/28/2022

      ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  9. Show article details.

    BRIEF-West Pharmaceutical Services Inc Says Board Now Has 11 Directors

    Reuters – 8:24 AM ET 07/27/2022

    West Pharmaceutical Services Inc (WST) : * West Pharmaceutical Services Inc (WST) - BOARD NOW HAS 11 DIRECTORS Source: [ID: https://bit.ly/3owvqQg] Further company coverage:

  10. Show article details.

    BRIEF-West Elects New Director To The Board

    Reuters – 6:27 AM ET 07/27/2022

    West Pharmaceutical Services Inc (WST) : * WEST ELECTS NEW DIRECTOR TO THE BOARD Source text for Eikon: Further company coverage:

  11. Show article details.

    West Elects New Director to the Board

    PR Newswire – 6:00 AM ET 07/27/2022

    EXTON, Pa., July 27, 2022 West Pharmaceutical Services (WST), Inc. , a global leader in innovative solutions for injectable drug administration, announced today the Company's Board of Directors has elected Stephen Lockhart, M.D., Ph.D., as its newest member. Northern California. Serving in this role for over seven years, he was responsible for quality, patient safety, research and education.

  12. Show article details.

    West to Host Second-Quarter 2022 Conference Call

    PR Newswire – 5:00 PM ET 07/14/2022

    EXTON, Pa., July 14, 2022 West Pharmaceutical Services, Inc. (WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2022 financial results before the market opens on Thursday, July 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

  13. Show article details.

    West Pharmaceutical Services Releases 2021 Corporate Responsibility Report

    PR Newswire – 3:00 PM ET 07/12/2022

    EXTON, Pa., July 12, 2022 West Pharmaceutical Services, Inc. (WST), a global leader in innovative solutions for injectable drug administration, has recently released its 2021 Corporate Responsibility Report, reporting on the Company's environmental, social, and governance performance in 2021.

  14. Show article details.

    West Introduces Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention

    PR Newswire – 6:00 AM ET 06/13/2022

    EXTON, Pa., June 13, 2022 West Pharmaceutical Services, Inc. , a global leader in innovative solutions for injectable drug administration, today announced that it will unveil its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention, taking place in San Diego, CA from June 13-16, 2022.

  15. Show article details.

    West Receives Exhibitor Award at INTERPHEX 2022 for Proprietary DeltaCube™ Modeling Platform

    PR Newswire – 4:30 PM ET 05/24/2022

    The DeltaCube™ Modeling Platform is an analytics platform aimed at container closure system selection, optimization, and usage EXTON, Pa., May 24, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (WST), a global leader in innovative solutions for injectable drug administration, today announced it received the Biotech Innovation Award for the DeltaCube™ Modeling Platform at the INTERPHEX 2022 T...

  16. Show article details.

    West to Attend and Showcase Industry Leadership in Packaging and Containment at INTERPHEX 2022

    PR Newswire – 4:30 PM ET 05/23/2022

    West to present on industry trends, enabling technologies, packaging components, and innovative DeltaCube™ Modeling Platform EXTON, Pa., May 23, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at INTERPHEX 2022 to showcase its leadership and expertise on industry challenges and...

  17. Show article details.

    West Pharmaceutical Services Shares Slides Post Q1 Results

    Benzinga – 11:15 AM ET 04/28/2022

    West Pharmaceutical Services Shares Slides Post Q1 Results

Page:

Today's and Upcoming Events

  • Oct
    26

    WST to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jul
    28

    WST announced Q2 earnings.

  • Jul
    19

    WST ex-Dividend for $0.18 on 07/19/2022

    • Announce Date: 04/28/2022
    • Record Date: 07/20/2022
    • Pay Date: 08/03/2022
Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.